618 related articles for article (PubMed ID: 32986498)
1. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
2. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
3. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF; Kipps TJ; Eichhorst BF; D'Rozario J; Owen CJ; Assouline S; Lamanna N; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Mellink C; Chyla B; Panchal A; Lu T; Wu JQ; Jiang Y; Lefebure M; Boyer M; Kater AP
Blood; 2022 Aug; 140(8):839-850. PubMed ID: 35605176
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Ma S; Seymour JF; Brander DM; Kipps TJ; Choi MY; Anderson MA; Humphrey K; Al Masud A; Pesko J; Nandam R; Salem AH; Chyla B; Arzt J; Jacobson A; Kim SY; Roberts AW
Blood; 2021 Sep; 138(10):836-846. PubMed ID: 34115103
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
6. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
[TBL] [Abstract][Full Text] [Related]
8. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR; Starza ID; Messina M; Reda G; Trentin L; Coscia M; Sportoletti P; Orsucci L; Arena V; Casaluci GM; Marasca R; Murru R; Laurenti L; Ilariucci F; Stelitano C; Mannina D; Massaia M; Rigolin GM; Scarfò L; Marchetti M; Levato L; Tani M; Arcari A; Musuraca G; Deodato M; Galieni P; Patrizi VB; Gottardi D; Liberati AM; Giordano A; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R
Haematologica; 2023 Aug; 108(8):2091-2100. PubMed ID: 36632738
[TBL] [Abstract][Full Text] [Related]
9. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Mato AR; Sharman JP; Biondo JML; Wu M; Mun Y; Kim SY; Humphrey K; Boyer M; Zhu Q; Seymour JF
Haematologica; 2022 Jan; 107(1):134-142. PubMed ID: 33327712
[TBL] [Abstract][Full Text] [Related]
10. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T; Cairns DA; Bloor A; Allsup D; Cwynarski K; Pettitt A; Paneesha S; Fox CP; Eyre TA; Forconi F; Elmusharaf N; Kennedy B; Gribben J; Pemberton N; Sheehy O; Preston G; Schuh A; Walewska R; Duley L; Howard D; Hockaday A; Jackson S; Greatorex N; Girvan S; Bell S; Brown JM; Webster N; Dalal S; de Tute R; Rawstron A; Patten PEM; Hillmen P;
N Engl J Med; 2024 Jan; 390(4):326-337. PubMed ID: 38078508
[TBL] [Abstract][Full Text] [Related]
11. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B; Niemann CU; Kater AP; Fürstenau M; von Tresckow J; Zhang C; Robrecht S; Gregor M; Juliusson G; Thornton P; Staber PB; Tadmor T; Lindström V; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Nösslinger T; Janssens A; Christiansen I; Baumann M; Frederiksen H; van der Klift M; Jäger U; Leys MBL; Hoogendoorn M; Lotfi K; Hebart H; Gaska T; Koene H; Enggaard L; Goede J; Regelink JC; Widmer A; Simon F; De Silva N; Fink AM; Bahlo J; Fischer K; Wendtner CM; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Levin MD; van Oers M; Geisler C; Stilgenbauer S; Hallek M;
N Engl J Med; 2023 May; 388(19):1739-1754. PubMed ID: 37163621
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
15. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M
Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865
[TBL] [Abstract][Full Text] [Related]
16. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
17. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract][Full Text] [Related]
19. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract][Full Text] [Related]
20. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
